GSK receives positive CHMP opinion recommending momelotinib for myelofibrosis patients with anaemia

Decision on EU marketing authorisation expected for momelotinib by early 2024

Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-mutant advanced non-small cell lung cancer

Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients

LG Chem initiates phase 2 clinical trials in patients with defects in MC4R pathway causing obesity and hyperphagia

LG Chem is making progress in the development of the world's first oral treatment for rare forms of obesity.

Lupin's Joint Airways Initiative surpasses 10,000 patients

Ojjaara approved in the US as the first and only treatment for myelofibrosis patients with anaemia

Approval is for use in myelofibrosis patients with anaemia regardless of prior myelofibrosis therapy

Lupin, Cost Plus Drug and COPD Foundation to expand access to medication for COPD patients

This collaboration marks a significant milestone in countering the disease burden by enhancing access to products for patients in the US

Mankind Pharma launches 120 premium DMF quality drugs for Indian Patients

Mankind Pharma's initiative aims to ensure universal access to medicines of international calibre

BlueRock’s Phase I study with bemdaneprocel in patients with Parkinson’s disease meets primary endpoint

Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year

Lupin launches ‘Jeet’ to raise awareness of cardiovascular disease among patients

Jeet will be a trusted partner in cardiovascular care

InnoCare gets approval of clinical trial of Zurletrectinib for the treatment of pediatric patients in China

Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes